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Background:  Acute myocardial infarction (AMI) is a recognized complication in patients with hypertrophic cardiomyopathy (HCM). 
However, there are limited data on outcomes of HCM patients presenting with AMI.
methods:  We queried the 2003-2011 Nationwide Inpatient Sample databases to identify all patients ≥18 years with the primary diagnosis 
of AMI. Patients with HCM were then identified using ICD-9-CM code 425.1. Logistic regression was used to compare treatment choice and 
outcomes in AMI patients with and without HCM.
results:  From 2003-2011, of 5,900,949 patients with AMI, 5,688 (0.1%) had a diagnosis of HCM. Patients with HCM were more likely 
to be older (71.4±13.9 years vs 67.8±14.5 years) and women (67.7% vs 40.2%). HCM patients were less likely to have traditional 
cardiovascular risk factors, including family history of coronary artery disease, dyslipidemia, obesity, smoking and diabetes mellitus. They 
were more likely to have congestive heart failure, atrial fibrillation, valvular diseases and prior history of cardiac arrest. HCM patients were 
less likely to have ST-elevation myocardial infarction (STEMI) (22.8% vs 37.5%, p<0.001). HCM patients with STEMI were less likely to 
receive thrombolysis (1.2% vs 3.8%, p<0.001) or percutaneous coronary intervention (PCI) (31.2% vs 56.8%, p<0.001). HCM patients with 
non-ST elevation myocardial infarction (NSTEMI) were less likely to receive PCI (14.9% vs 30.8%, p<0.001) or coronary artery bypass 
surgery (4.7% vs 9.6%, p<0.001). Among patients with STEMI, patients with HCM had 24% lower in-hospital mortality than patients without 
HCM (adjusted OR 0.76, 95 % CI 0.63-0.91, p=0.004). After further adjustment for treatment received, HCM patients with STEMI had 33% 
lower in-hospital mortality than patients without HCM (adjusted OR 0.67, 95% CI 0.55-0.80, p<0.001). Among patients with NSTEMI, there 
was no difference in in-hospital mortality in patients with and without HCM (p=0.91) (interaction p value for HCM and STEMI = 0.039).
conclusion:  HCM patients represent a small portion of patients with AMI and are less likely to be treated with revascularization. 
Compared to patients without HCM, HCM patients with STEMI have lower in-hospital mortality.
